{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T18:42:56Z","timestamp":1794336176885,"version":"4.9.0"},"reference-count":118,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T00:00:00Z","timestamp":1776729600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T00:00:00Z","timestamp":1781481600000},"content-version":"vor","delay-in-days":55,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"AvL Foundation Oncode"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-026-72178-1","type":"journal-article","created":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T09:46:06Z","timestamp":1776764766000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Microbiota-derived metabolites as modulators of cancer immunotherapy response"],"prefix":"10.1038","volume":"17","author":[{"given":"Catherine","family":"Toner-Bartelds","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iris L.","family":"Mimpen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Parra-Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4044-9596","authenticated-orcid":false,"given":"Boudewijn M. T.","family":"Burgering","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8249-9586","authenticated-orcid":false,"given":"Emile E.","family":"Voest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,21]]},"reference":[{"key":"72178_CR1","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.semcancer.2020.06.016","volume":"79","author":"N Gaynor","year":"2022","unstructured":"Gaynor, N., Crown, J. & Collins, D. M. Immune checkpoint inhibitors: key trials and an emerging role in breast cancer. Semin. Cancer Biol. 79, 44\u201357 (2022).","journal-title":"Semin. Cancer Biol."},{"key":"72178_CR2","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1186\/s40425-019-0805-8","volume":"7","author":"S Das","year":"2019","unstructured":"Das, S. & Johnson, D. B. Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors. J. Immunother. Cancer 7, 306 (2019).","journal-title":"J. Immunother. Cancer"},{"key":"72178_CR3","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","volume":"12","author":"D Hanahan","year":"2022","unstructured":"Hanahan, D. Hallmarks of cancer: new dimensions. Cancer Discov. 12, 31\u201346 (2022).","journal-title":"Cancer Discov."},{"key":"72178_CR4","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1007\/s00262-019-02453-2","volume":"69","author":"BE Wilson","year":"2020","unstructured":"Wilson, B. E., Routy, B., Nagrial, A. & Chin, V. T. The effect of antibiotics on clinical outcomes in immune-checkpoint blockade: a systematic review and meta-analysis of observational studies. Cancer Immunol. Immunother. 69, 343\u2013354 (2020).","journal-title":"Cancer Immunol. Immunother."},{"key":"72178_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-024-00630-w","volume":"8","author":"A Elkrief","year":"2024","unstructured":"Elkrief, A. et al. Antibiotics are associated with worse outcomes in lung cancer patients treated with chemotherapy and immunotherapy. NPJ Precis Oncol. 8, 143 (2024).","journal-title":"NPJ Precis Oncol."},{"key":"72178_CR6","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1126\/science.aan3706","volume":"359","author":"B Routy","year":"2018","unstructured":"Routy, B. et al. Gut microbiome influences efficacy of PD-1\u2013based immunotherapy against epithelial tumors. Science 359, 91\u201397 (2018).","journal-title":"Science"},{"key":"72178_CR7","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1126\/science.aac4255","volume":"350","author":"A Sivan","year":"2015","unstructured":"Sivan, A. et al. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science 350, 1084\u20131089 (2015).","journal-title":"Science"},{"key":"72178_CR8","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1126\/science.aan4236","volume":"359","author":"V Gopalakrishnan","year":"2018","unstructured":"Gopalakrishnan, V. et al. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science 359, 97\u2013103 (2018).","journal-title":"Science"},{"key":"72178_CR9","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1038\/s41591-022-01695-5","volume":"28","author":"KA Lee","year":"2022","unstructured":"Lee, K. A. et al. Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma. Nat. Med. 28, 535\u2013544 (2022).","journal-title":"Nat. Med."},{"key":"72178_CR10","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1126\/science.abf3363","volume":"371","author":"D Davar","year":"2021","unstructured":"Davar, D. et al. Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patients. Science 371, 595\u2013602 (2021).","journal-title":"Science"},{"key":"72178_CR11","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1126\/science.abb5920","volume":"371","author":"EN Baruch","year":"2021","unstructured":"Baruch, E. N. et al. Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients. Science 371, 602\u2013609 (2021).","journal-title":"Science"},{"key":"72178_CR12","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1038\/s41591-023-02453-x","volume":"29","author":"B Routy","year":"2023","unstructured":"Routy, B. et al. Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trial. Nat. Med. 29, 2121\u20132132 (2023).","journal-title":"Nat. Med."},{"key":"72178_CR13","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1158\/2326-6066.CIR-20-0051","volume":"8","author":"Y Tomita","year":"2020","unstructured":"Tomita, Y. et al. Association of probiotic clostridium butyricum therapy with survival and response to immune checkpoint blockade in patients with lung cancer. Cancer Immunol. Res. 8, 1236\u20131242 (2020).","journal-title":"Cancer Immunol. Res."},{"key":"72178_CR14","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1002\/ijc.33557","volume":"149","author":"K Takada","year":"2021","unstructured":"Takada, K. et al. Clinical impact of probiotics on the efficacy of anti-PD-1 monotherapy in patients with nonsmall cell lung cancer: a multicenter retrospective survival analysis study with inverse probability of treatment weighting. Int. J. Cancer 149, 473\u2013482 (2021).","journal-title":"Int. J. Cancer"},{"key":"72178_CR15","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1038\/s41591-022-01694-6","volume":"28","author":"N Dizman","year":"2022","unstructured":"Dizman, N. et al. Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial. Nat. Med. 28, 704\u2013712 (2022).","journal-title":"Nat. Med."},{"key":"72178_CR16","doi-asserted-by":"crossref","unstructured":"The Human Microbiome Project Consortium. Structure, function and diversity of the healthy human microbiome. Nature 486, 207\u2013214 (2012).","DOI":"10.1038\/nature11234"},{"key":"72178_CR17","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1038\/nm.4517","volume":"24","author":"JA Gilbert","year":"2018","unstructured":"Gilbert, J. A. et al. Current understanding of the human microbiome. Nat. Med. 24, 392\u2013400 (2018).","journal-title":"Nat. Med."},{"key":"72178_CR18","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2022.863407","volume":"13","author":"C Li","year":"2022","unstructured":"Li, C., Liang, Y. & Qiao, Y. Messengers from the gut: gut microbiota-derived metabolites on host regulation. Front. Microbiol 13, 863407 (2022).","journal-title":"Front. Microbiol"},{"key":"72178_CR19","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1038\/s41579-020-0438-4","volume":"19","author":"KA Krautkramer","year":"2021","unstructured":"Krautkramer, K. A., Fan, J. & B\u00e4ckhed, F. Gut microbial metabolites as multi-kingdom intermediates. Nat. Rev. Microbiol. 19, 77\u201394 (2021).","journal-title":"Nat. Rev. Microbiol."},{"key":"72178_CR20","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1038\/s41587-023-01675-1","volume":"41","author":"V Pascal Andreu","year":"2023","unstructured":"Pascal Andreu, V. et al. gutSMASH predicts specialized primary metabolic pathways from the human gut microbiota. Nat. Biotechnol. 41, 1416\u20131423 (2023).","journal-title":"Nat. Biotechnol."},{"key":"72178_CR21","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.immuni.2022.01.006","volume":"55","author":"K Hezaveh","year":"2022","unstructured":"Hezaveh, K. et al. Tryptophan-derived microbial metabolites activate the aryl hydrocarbon receptor in tumor-associated macrophages to suppress anti-tumor immunity. Immunity 55, 324\u2013340 e328 (2022).","journal-title":"Immunity"},{"key":"72178_CR22","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abn0704","volume":"7","author":"G Mirji","year":"2022","unstructured":"Mirji, G. et al. The microbiome-derived metabolite TMAO drives immune activation and boosts responses to immune checkpoint blockade in pancreatic cancer. Sci. Immunol. 7, eabn0704 (2022).","journal-title":"Sci. Immunol."},{"key":"72178_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/srep16148","volume":"5","author":"C Nastasi","year":"2015","unstructured":"Nastasi, C. et al. The effect of short-chain fatty acids on human monocyte-derived dendritic cells. Sci. Rep. 5, 16148 (2015).","journal-title":"Sci. Rep."},{"key":"72178_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-16079-x","volume":"11","author":"C Coutzac","year":"2020","unstructured":"Coutzac, C. et al. Systemic short chain fatty acids limit antitumor effect of CTLA-4 blockade in hosts with cancer. Nat. Commun. 11, 2168 (2020).","journal-title":"Nat. Commun."},{"key":"72178_CR25","doi-asserted-by":"crossref","unstructured":"Perez, M., Buey, B., Corral, P., Giraldos, D. & Latorre, E. Microbiota-derived short-chain fatty acids boost antitumoral natural killer cell activity. J. Clin. Med. 13, 3885 (2024).","DOI":"10.3390\/jcm13133885"},{"key":"72178_CR26","doi-asserted-by":"publisher","DOI":"10.34133\/research.0127","volume":"6","author":"N Liu","year":"2023","unstructured":"Liu, N. et al. Eubacterium rectale improves the efficacy of anti-PD1 immunotherapy in melanoma via L-serine-mediated NK cell activation. Research 6, 0127 (2023).","journal-title":"Research"},{"key":"72178_CR27","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1038\/nature11743","volume":"493","author":"ODK Maddocks","year":"2013","unstructured":"Maddocks, O. D. K. et al. Serine starvation induces stress and p53-dependent metabolic remodelling in cancer cells. Nature 493, 542\u2013546 (2013).","journal-title":"Nature"},{"key":"72178_CR28","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1038\/nature22056","volume":"544","author":"ODK Maddocks","year":"2017","unstructured":"Maddocks, O. D. K. et al. Modulating the therapeutic response of tumours to dietary serine and glycine starvation. Nature 544, 372\u2013376 (2017).","journal-title":"Nature"},{"key":"72178_CR29","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1016\/j.cell.2023.02.032","volume":"186","author":"J Gungabeesoon","year":"2023","unstructured":"Gungabeesoon, J. et al. A neutrophil response linked to tumor control in immunotherapy. Cell 186, 1448\u20131464.e1420 (2023).","journal-title":"Cell"},{"key":"72178_CR30","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1016\/j.cell.2024.02.005","volume":"187","author":"Y Wu","year":"2024","unstructured":"Wu, Y. et al. Neutrophil profiling illuminates anti-tumor antigen-presenting potency. Cell 187, 1422\u20131439.e1424 (2024).","journal-title":"Cell"},{"key":"72178_CR31","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.ccell.2022.11.014","volume":"41","author":"OS Blomberg","year":"2023","unstructured":"Blomberg, O. S. et al. IL-5-producing CD4+ T cells and eosinophils cooperate to enhance response to immune checkpoint blockade in breast cancer. Cancer Cell 41, 106\u2013123.e110 (2023).","journal-title":"Cancer Cell"},{"key":"72178_CR32","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1038\/s41577-020-00452-4","volume":"21","author":"JC Ribot","year":"2021","unstructured":"Ribot, J. C., Lopes, N. & Silva-Santos, B. gammadelta T cells in tissue physiology and surveillance. Nat. Rev. Immunol. 21, 221\u2013232 (2021).","journal-title":"Nat. Rev. Immunol."},{"key":"72178_CR33","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1127588","volume":"14","author":"MF Jabeen","year":"2023","unstructured":"Jabeen, M. F. & Hinks, T. S. C. MAIT cells and the microbiome. Front. Immunol. 14, 1127588 (2023).","journal-title":"Front. Immunol."},{"key":"72178_CR34","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2021.718350","volume":"11","author":"S Vogt","year":"2021","unstructured":"Vogt, S. & Mattner, J. NKT cells contribute to the control of microbial infections. Front. Cell Infect. Microbiol 11, 718350 (2021).","journal-title":"Front. Cell Infect. Microbiol"},{"key":"72178_CR35","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1038\/s41568-023-00562-w","volume":"23","author":"B Ruf","year":"2023","unstructured":"Ruf, B., Greten, T. F. & Korangy, F. Innate lymphoid cells and innate-like T cells in cancer\u2014at the crossroads of innate and adaptive immunity. Nat. Rev. Cancer 23, 351\u2013371 (2023).","journal-title":"Nat. Rev. Cancer"},{"key":"72178_CR36","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/S0014-5793(01)03191-X","volume":"509","author":"M Hintz","year":"2001","unstructured":"Hintz, M. et al. Identification of (E)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate as a major activator for human gammadelta T cells in Escherichia coli. FEBS Lett. 509, 317\u2013322 (2001).","journal-title":"FEBS Lett."},{"key":"72178_CR37","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.645131","volume":"12","author":"G Holmen Olofsson","year":"2021","unstructured":"Holmen Olofsson, G. et al. Vgamma9Vdelta2 T cells concurrently kill cancer cells and cross-present tumor antigens. Front. Immunol. 12, 645131 (2021).","journal-title":"Front. Immunol."},{"key":"72178_CR38","doi-asserted-by":"crossref","unstructured":"Mimpen, I. L. et al. Microbial metabolic pathways guide response to immune checkpoint blockade therapy. Cancer Discov. 16, 95\u2013113 (2025).","DOI":"10.1158\/2159-8290.CD-24-1669"},{"key":"72178_CR39","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1038\/nature11605","volume":"491","author":"L Kjer-Nielsen","year":"2012","unstructured":"Kjer-Nielsen, L. et al. MR1 presents microbial vitamin B metabolites to MAIT cells. Nature 491, 717\u2013723 (2012).","journal-title":"Nature"},{"key":"72178_CR40","doi-asserted-by":"publisher","first-page":"30204","DOI":"10.1074\/jbc.R115.685990","volume":"290","author":"SB Eckle","year":"2015","unstructured":"Eckle, S. B. et al. Recognition of vitamin B precursors and byproducts by mucosal associated invariant T Cells. J. Biol. Chem. 290, 30204\u201330211 (2015).","journal-title":"J. Biol. Chem."},{"key":"72178_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2020.100039","volume":"1","author":"S Li","year":"2020","unstructured":"Li, S. et al. Human Tumor-infiltrating MAIT cells display hallmarks of bacterial antigen recognition in colorectal cancer. Cell Rep. Med. 1, 100039 (2020).","journal-title":"Cell Rep. Med."},{"key":"72178_CR42","doi-asserted-by":"crossref","unstructured":"Ma, C. et al. Gut microbiome-mediated bile acid metabolism regulates liver cancer via NKT cells. Science 360, eaan5931 (2018).","DOI":"10.1126\/science.aan5931"},{"key":"72178_CR43","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.cellimm.2015.04.008","volume":"296","author":"EJ Adams","year":"2015","unstructured":"Adams, E. J., Gu, S. & Luoma, A. M. Human gamma delta T cells: evolution and ligand recognition. Cell Immunol. 296, 31\u201340 (2015).","journal-title":"Cell Immunol."},{"key":"72178_CR44","doi-asserted-by":"publisher","first-page":"2731","DOI":"10.4049\/jimmunol.172.5.2731","volume":"172","author":"J Mestas","year":"2004","unstructured":"Mestas, J. & Hughes, C. C. Of mice and not men: differences between mouse and human immunology. J. Immunol. 172, 2731\u20132738 (2004).","journal-title":"J. Immunol."},{"key":"72178_CR45","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.molimm.2020.12.003","volume":"130","author":"M Salou","year":"2021","unstructured":"Salou, M., Legoux, F. & Lantz, O. MAIT cell development in mice and humans. Mol. Immunol. 130, 31\u201336 (2021).","journal-title":"Mol. Immunol."},{"key":"72178_CR46","doi-asserted-by":"crossref","unstructured":"Phelps, C. M. et al. Exercise-induced microbiota metabolite enhances CD8 T cell antitumor immunity promoting immunotherapy efficacy. Cell 188, 5680\u20135700 (2025).","DOI":"10.1016\/j.cell.2025.06.018"},{"key":"72178_CR47","doi-asserted-by":"publisher","first-page":"1846","DOI":"10.1016\/j.cell.2023.03.011","volume":"186","author":"MJ Bender","year":"2023","unstructured":"Bender, M. J. et al. Dietary tryptophan metabolite released by intratumoral Lactobacillus reuteri facilitates immune checkpoint inhibitor treatment. Cell 186, 1846\u20131862 e1826 (2023).","journal-title":"Cell"},{"key":"72178_CR48","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1158\/2159-8290.CD-24-1230","volume":"15","author":"L Marcos-Kovandzic","year":"2025","unstructured":"Marcos-Kovandzic, L. et al. Gut microbiota modulation through akkermansia spp. supplementation increases CAR T-cell potency. Cancer Discov. 15, 1905\u20131926 (2025).","journal-title":"Cancer Discov."},{"key":"72178_CR49","doi-asserted-by":"publisher","first-page":"2336","DOI":"10.1016\/j.cell.2025.02.029","volume":"188","author":"WB Jin","year":"2025","unstructured":"Jin, W. B. et al. Microbiota-derived bile acids antagonize the host androgen receptor and drive anti-tumor immunity. Cell 188, 2336\u20132353 e2338 (2025).","journal-title":"Cell"},{"key":"72178_CR50","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1126\/science.adl4100","volume":"387","author":"SK Varanasi","year":"2025","unstructured":"Varanasi, S. K. et al. Bile acid synthesis impedes tumor-specific T cell responses during liver cancer. Science 387, 192\u2013201 (2025).","journal-title":"Science"},{"key":"72178_CR51","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-24331-1","volume":"12","author":"M Luu","year":"2021","unstructured":"Luu, M. et al. Microbial short-chain fatty acids modulate CD8(+) T cell responses and improve adoptive immunotherapy for cancer. Nat. Commun. 12, 4077 (2021).","journal-title":"Nat. Commun."},{"key":"72178_CR52","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1016\/j.ccell.2024.08.019","volume":"42","author":"X Wang","year":"2024","unstructured":"Wang, X. et al. Fusobacterium nucleatum facilitates anti-PD-1 therapy in microsatellite stable colorectal cancer. Cancer Cell 42, 1729\u20131746 e1728 (2024).","journal-title":"Cancer Cell"},{"key":"72178_CR53","doi-asserted-by":"publisher","DOI":"10.1080\/19490976.2023.2249143","volume":"15","author":"X Zhu","year":"2023","unstructured":"Zhu, X. et al. Microbial metabolite butyrate promotes anti-PD-1 antitumor efficacy by modulating T cell receptor signaling of cytotoxic CD8 T cell. Gut Microbes 15, 2249143 (2023).","journal-title":"Gut Microbes"},{"key":"72178_CR54","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1016\/j.cell.2024.02.022","volume":"187","author":"D Jia","year":"2024","unstructured":"Jia, D. et al. Microbial metabolite enhances immunotherapy efficacy by modulating T cell stemness in pan-cancer. Cell 187, 1651\u20131665 e1621 (2024).","journal-title":"Cell"},{"key":"72178_CR55","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1126\/science.abc3421","volume":"369","author":"LF Mager","year":"2020","unstructured":"Mager, L. F. et al. Microbiome-derived inosine modulates response to checkpoint inhibitor immunotherapy. Science 369, 1481\u20131489 (2020).","journal-title":"Science"},{"key":"72178_CR56","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.1136\/gutjnl-2023-330291","volume":"72","author":"X Kang","year":"2023","unstructured":"Kang, X. et al. Roseburia intestinalis generated butyrate boosts anti-PD-1 efficacy in colorectal cancer by activating cytotoxic CD8(+) T cells. Gut 72, 2112\u20132122 (2023).","journal-title":"Gut"},{"key":"72178_CR57","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1016\/j.cmet.2024.12.013","volume":"37","author":"X Zhu","year":"2025","unstructured":"Zhu, X. et al. Interplay between gut microbial communities and metabolites modulates pan-cancer immunotherapy responses. Cell Metab. 37, 806\u2013823 e806 (2025).","journal-title":"Cell Metab."},{"key":"72178_CR58","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1248\/bpb.b17-00799","volume":"41","author":"M Hazekawa","year":"2018","unstructured":"Hazekawa, M., Ono, K., Nishinakagawa, T., Kawakubo-Yasukochi, T. & Nakashima, M. In vitro anti-inflammatory effects of the phenylbutyric acid metabolite phenylacetyl glutamine. Biol. Pharm. Bull. 41, 961\u2013966 (2018).","journal-title":"Biol. Pharm. Bull."},{"key":"72178_CR59","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1016\/j.immuni.2022.09.014","volume":"55","author":"D Denk","year":"2022","unstructured":"Denk, D. et al. Expansion of T memory stem cells with superior anti-tumor immunity by Urolithin A-induced mitophagy. Immunity 55, 2059\u20132073 e2058 (2022).","journal-title":"Immunity"},{"key":"72178_CR60","doi-asserted-by":"publisher","first-page":"2415","DOI":"10.1016\/j.cmet.2021.11.010","volume":"33","author":"M St Paul","year":"2021","unstructured":"St Paul, M. et al. Coenzyme A fuels T cell anti-tumor immunity. Cell Metab. 33, 2415\u20132427 e2416 (2021).","journal-title":"Cell Metab."},{"key":"72178_CR61","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1158\/2643-3230.BCD-24-0203","volume":"6","author":"M Uribe-Herranz","year":"2025","unstructured":"Uribe-Herranz, M. et al. Microbiota shape metabolic and immune determinants of CAR-T therapy and correlate with outcomes in myeloma. Blood Cancer Discov. 6, 484\u2013504 (2025).","journal-title":"Blood Cancer Discov."},{"key":"72178_CR62","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-31141-6","volume":"13","author":"Y Shen","year":"2022","unstructured":"Shen, Y. et al. Ursodeoxycholic acid reduces antitumor immunosuppression by inducing CHIP-mediated TGF-beta degradation. Nat. Commun. 13, 3419 (2022).","journal-title":"Nat. Commun."},{"key":"72178_CR63","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-33116-z","volume":"13","author":"L Zhang","year":"2022","unstructured":"Zhang, L. et al. Inhibition of UBA6 by inosine augments tumour immunogenicity and responses. Nat. Commun. 13, 5413 (2022).","journal-title":"Nat. Commun."},{"key":"72178_CR64","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1016\/j.ccell.2023.08.014","volume":"41","author":"V Ferrari","year":"2023","unstructured":"Ferrari, V. et al. Sensitizing cancer cells to immune checkpoint inhibitors by microbiota-mediated upregulation of HLA class I. Cancer Cell 41, 1717\u20131730 e1714 (2023).","journal-title":"Cancer Cell"},{"key":"72178_CR65","doi-asserted-by":"crossref","unstructured":"Zhang, J. et al. Targeting gut microbiota and arginase boosts MEK inhibitors\u2019 enhancement of antitumour immunity via MHC-I upregulation in colorectal cancer. Br. J. Cancer 133, 809\u2013822 (2025).","DOI":"10.1038\/s41416-025-03106-1"},{"key":"72178_CR66","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-56498-2","volume":"16","author":"Y Teng","year":"2025","unstructured":"Teng, Y. et al. Plant-nanoparticles enhance anti-PD-L1 efficacy by shaping human commensal microbiota metabolites. Nat. Commun. 16, 1295 (2025).","journal-title":"Nat. Commun."},{"key":"72178_CR67","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-024-05762-y","volume":"22","author":"B Wang","year":"2024","unstructured":"Wang, B. et al. Blautia coccoides and its metabolic products enhance the efficacy of bladder cancer immunotherapy by promoting CD8(+) T cell infiltration. J. Transl. Med. 22, 964 (2024).","journal-title":"J. Transl. Med."},{"key":"72178_CR68","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1016\/j.chom.2025.04.022","volume":"33","author":"M Zhang","year":"2025","unstructured":"Zhang, M. et al. Microbiota-derived urocanic acid triggered by tyrosine kinase inhibitors potentiates cancer immunotherapy efficacy. Cell Host Microbe 33, 915\u2013931 e919 (2025).","journal-title":"Cell Host Microbe"},{"key":"72178_CR69","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/j.chom.2023.04.010","volume":"31","author":"SS Jiang","year":"2023","unstructured":"Jiang, S. S. et al. Fusobacterium nucleatum-derived succinic acid induces tumor resistance to immunotherapy in colorectal cancer. Cell Host Microbe 31, 781\u2013797 e789 (2023).","journal-title":"Cell Host Microbe"},{"key":"72178_CR70","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/j.cmet.2022.02.010","volume":"34","author":"H Wang","year":"2022","unstructured":"Wang, H. et al. The microbial metabolite trimethylamine N-oxide promotes antitumor immunity in triple-negative breast cancer. Cell Metab. 34, 581\u2013594 e588 (2022).","journal-title":"Cell Metab."},{"key":"72178_CR71","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1038\/s41392-021-00507-5","volume":"6","author":"P Yu","year":"2021","unstructured":"Yu, P. et al. Pyroptosis: mechanisms and diseases. Signal Transduct. Target Ther. 6, 128 (2021).","journal-title":"Signal Transduct. Target Ther."},{"key":"72178_CR72","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1111\/imcb.12798","volume":"102","author":"P Sardar","year":"2024","unstructured":"Sardar, P., Almeida, A. & Pedicord, V. A. Integrating functional metagenomics to decipher microbiome-immune interactions. Immunol. Cell Biol. 102, 680\u2013691 (2024).","journal-title":"Immunol. Cell Biol."},{"key":"72178_CR73","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/s41579-021-00621-9","volume":"20","author":"A Bauermeister","year":"2022","unstructured":"Bauermeister, A., Mannochio-Russo, H., Costa-Lotufo, L. V., Jarmusch, A. K. & Dorrestein, P. C. Mass spectrometry-based metabolomics in microbiome investigations. Nat. Rev. Microbiol. 20, 143\u2013160 (2022).","journal-title":"Nat. Rev. Microbiol."},{"key":"72178_CR74","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.ijmm.2016.03.006","volume":"306","author":"KS Smirnov","year":"2016","unstructured":"Smirnov, K. S. et al. Challenges of metabolomics in human gut microbiota research. Int. J. Med Microbiol. 306, 266\u2013279 (2016).","journal-title":"Int. J. Med Microbiol."},{"key":"72178_CR75","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1016\/j.ccell.2024.07.005","volume":"42","author":"Y Sun","year":"2024","unstructured":"Sun, Y. et al. Integrative plasma and fecal metabolomics identify functional metabolites in adenoma-colorectal cancer progression and as early diagnostic biomarkers. Cancer Cell 42, 1386\u20131400.e1388 (2024).","journal-title":"Cancer Cell"},{"key":"72178_CR76","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1038\/s41591-021-01552-x","volume":"27","author":"C Mirzayi","year":"2021","unstructured":"Mirzayi, C. et al. Reporting guidelines for human microbiome research: the STORMS checklist. Nat. Med. 27, 1885\u20131892 (2021).","journal-title":"Nat. Med."},{"key":"72178_CR77","unstructured":"Action, H. M. <https:\/\/humanmicrobiomeaction.eu> ("},{"key":"72178_CR78","doi-asserted-by":"publisher","first-page":"846","DOI":"10.3390\/cancers16050846","volume":"16","author":"S Ferri-Borgogno","year":"2024","unstructured":"Ferri-Borgogno, S. et al. Molecular, metabolic, and subcellular mapping of the tumor immune microenvironment via 3D targeted and non-targeted multiplex multi-omics analyses. Cancers 16, 846 (2024).","journal-title":"Cancers"},{"key":"72178_CR79","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1038\/s42255-023-00881-0","volume":"5","author":"T Alexandrov","year":"2023","unstructured":"Alexandrov, T. Spatial metabolomics: from a niche field towards a driver of innovation. Nat. Metab. 5, 1443\u20131445 (2023).","journal-title":"Nat. Metab."},{"key":"72178_CR80","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1038\/s41590-019-0416-z","volume":"20","author":"TM Allen","year":"2019","unstructured":"Allen, T. M. et al. Humanized immune system mouse models: progress, challenges and opportunities. Nat. Immunol. 20, 770\u2013774 (2019).","journal-title":"Nat. Immunol."},{"key":"72178_CR81","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s00018-017-2693-8","volume":"75","author":"F Hugenholtz","year":"2018","unstructured":"Hugenholtz, F. & de Vos, W. M. Mouse models for human intestinal microbiota research: a critical evaluation. Cell Mol. Life Sci. 75, 149\u2013160 (2018).","journal-title":"Cell Mol. Life Sci."},{"key":"72178_CR82","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.cell.2015.08.068","volume":"163","author":"CP Day","year":"2015","unstructured":"Day, C. P., Merlino, G. & Van Dyke, T. Preclinical mouse cancer models: a maze of opportunities and challenges. Cell 163, 39\u201353 (2015).","journal-title":"Cell"},{"key":"72178_CR83","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1038\/s12276-020-0473-2","volume":"52","author":"JC Park","year":"2020","unstructured":"Park, J. C. & Im, S.-H. Of men in mice: the development and application of a humanized gnotobiotic mouse model for microbiome therapeutics. Exp. Mol. Med. 52, 1383\u20131396 (2020).","journal-title":"Exp. Mol. Med."},{"key":"72178_CR84","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-13930-7","volume":"12","author":"E Shelkey","year":"2022","unstructured":"Shelkey, E. et al. Immuno-reactive cancer organoid model to assess effects of the microbiome on cancer immunotherapy. Sci. Rep. 12, 9983 (2022).","journal-title":"Sci. Rep."},{"key":"72178_CR85","doi-asserted-by":"publisher","first-page":"4633","DOI":"10.1038\/s41596-021-00589-z","volume":"16","author":"J Puschhof","year":"2021","unstructured":"Puschhof, J. et al. Intestinal organoid cocultures with microbes. Nat. Protoc. 16, 4633\u20134649 (2021).","journal-title":"Nat. Protoc."},{"key":"72178_CR86","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1038\/s41551-024-01318-z","volume":"9","author":"M Ballerini","year":"2025","unstructured":"Ballerini, M. et al. A gut-on-a-chip incorporating human faecal samples and peristalsis predicts responses to immune checkpoint inhibitors for melanoma. Nat. Biomed. Eng. 9, 967\u2013984 (2025).","journal-title":"Nat. Biomed. Eng."},{"key":"72178_CR87","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/s44222-023-00130-9","volume":"2","author":"YC Shin","year":"2024","unstructured":"Shin, Y. C., Than, N., Min, S., Shin, W. & Kim, H. J. Modelling host\u2013microbiome interactions in organ-on-a-chip platforms. Nat. Rev. Bioeng. 2, 175\u2013191 (2024).","journal-title":"Nat. Rev. Bioeng."},{"key":"72178_CR88","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1038\/s41591-021-01398-3","volume":"27","author":"P Voabil","year":"2021","unstructured":"Voabil, P. et al. An ex vivo tumor fragment platform to dissect response to PD-1 blockade in cancer. Nat. Med 27, 1250\u20131261 (2021).","journal-title":"Nat. Med"},{"key":"72178_CR89","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1126\/science.aaz7015","volume":"374","author":"CN Spencer","year":"2021","unstructured":"Spencer, C. N. et al. Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response. Science 374, 1632\u20131640 (2021).","journal-title":"Science"},{"key":"72178_CR90","doi-asserted-by":"publisher","first-page":"2344","DOI":"10.1038\/s41591-022-01965-2","volume":"28","author":"RC Simpson","year":"2022","unstructured":"Simpson, R. C. et al. Diet-driven microbial ecology underpins associations between cancer immunotherapy outcomes and the gut microbiome. Nat. Med. 28, 2344\u20132352 (2022).","journal-title":"Nat. Med."},{"key":"72178_CR91","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-024-13234-1","volume":"24","author":"RM Farias","year":"2024","unstructured":"Farias, R. M. et al. Diet and immune effects trial (DIET)\u2014a randomized, double-blinded dietary intervention study in patients with melanoma receiving immunotherapy. BMC Cancer 24, 1493 (2024).","journal-title":"BMC Cancer"},{"key":"72178_CR92","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1158\/2159-8290.CD-21-0808","volume":"12","author":"M Messaoudene","year":"2022","unstructured":"Messaoudene, M. et al. A natural polyphenol exerts antitumor activity and circumvents anti-PD-1 resistance through effects on the gut microbiota. Cancer Discov. 12, 1070\u20131087 (2022).","journal-title":"Cancer Discov."},{"key":"72178_CR93","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1038\/s41551-021-00749-2","volume":"5","author":"K Han","year":"2021","unstructured":"Han, K. et al. Generation of systemic antitumour immunity via the in situ modulation of the gut microbiome by an orally administered inulin gel. Nat. Biomed. Eng. 5, 1377\u20131388 (2021).","journal-title":"Nat. Biomed. Eng."},{"key":"72178_CR94","doi-asserted-by":"publisher","first-page":"2468","DOI":"10.1158\/0008-5472.CAN-24-3209","volume":"85","author":"C Zhang","year":"2025","unstructured":"Zhang, C. et al. Mannose enhances immunotherapy efficacy in ovarian cancer by modulating gut microbial metabolites. Cancer Res. 85, 2468\u20132484 (2025).","journal-title":"Cancer Res."},{"key":"72178_CR95","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.105833","volume":"10","author":"IP da Silva","year":"2025","unstructured":"da Silva, I. P. et al. Retreatment, rechallenge, and escalation with subsequent immune checkpoint inhibitor therapies across cancers after initial failure. ESMO Open 10, 105833 (2025).","journal-title":"ESMO Open"},{"key":"72178_CR96","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1038\/s41586-021-04003-2","volume":"598","author":"FP Canale","year":"2021","unstructured":"Canale, F. P. et al. Metabolic modulation of tumours with engineered bacteria for immunotherapy. Nature 598, 662\u2013666 (2021).","journal-title":"Nature"},{"key":"72178_CR97","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1038\/s44319-025-00386-9","volume":"26","author":"TH Vaaben","year":"2025","unstructured":"Vaaben, T. H. et al. Modulating tumor immunity using advanced microbiome therapeutics producing an indole metabolite. EMBO Rep. 26, 1688\u20131708 (2025).","journal-title":"EMBO Rep."},{"key":"72178_CR98","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1038\/s41564-025-02108-2","volume":"10","author":"A Bignaud","year":"2025","unstructured":"Bignaud, A. et al. Phages with a broad host range are common across ecosystems. Nat. Microbiol. 10, 2537\u20132549 (2025).","journal-title":"Nat. Microbiol."},{"key":"72178_CR99","doi-asserted-by":"crossref","unstructured":"Wirbel, J. et al. Long-read metagenomics reveals phage dynamics in the human gut microbiome. Nature 649, 982\u2013990 (2025).","DOI":"10.1038\/s41586-025-09786-2"},{"key":"72178_CR100","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/S1473-3099(18)30482-1","volume":"19","author":"P Jault","year":"2019","unstructured":"Jault, P. et al. Efficacy and tolerability of a cocktail of bacteriophages to treat burn wounds infected by Pseudomonas aeruginosa (PhagoBurn): a randomised, controlled, double-blind phase 1\/2 trial. Lancet Infect. Dis. 19, 35\u201345 (2019).","journal-title":"Lancet Infect. Dis."},{"key":"72178_CR101","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/s41564-019-0634-z","volume":"5","author":"A Petrovic Fabijan","year":"2020","unstructured":"Petrovic Fabijan, A. et al. Safety of bacteriophage therapy in severe Staphylococcus aureus infection. Nat. Microbiol. 5, 465\u2013472 (2020).","journal-title":"Nat. Microbiol."},{"key":"72178_CR102","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1016\/j.chom.2025.05.004","volume":"33","author":"X Ding","year":"2025","unstructured":"Ding, X. et al. Bacteroides fragilis promotes chemoresistance in colorectal cancer, and its elimination by phage VA7 restores chemosensitivity. Cell Host Microbe 33, 941\u2013956 e910 (2025).","journal-title":"Cell Host Microbe"},{"key":"72178_CR103","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1038\/s41551-019-0423-2","volume":"3","author":"DW Zheng","year":"2019","unstructured":"Zheng, D. W. et al. Phage-guided modulation of the gut microbiota of mouse models of colorectal cancer augments their responses to chemotherapy. Nat. Biomed. Eng. 3, 717\u2013728 (2019).","journal-title":"Nat. Biomed. Eng."},{"key":"72178_CR104","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1016\/j.immuni.2024.02.014","volume":"57","author":"J Cong","year":"2024","unstructured":"Cong, J. et al. Bile acids modified by the intestinal microbiota promote colorectal cancer growth by suppressing CD8(+) T cell effector functions. Immunity 57, 876\u2013889 e811 (2024).","journal-title":"Immunity"},{"key":"72178_CR105","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/j.chom.2019.05.001","volume":"25","author":"BB Hsu","year":"2019","unstructured":"Hsu, B. B. et al. Dynamic modulation of the gut microbiota and metabolome by bacteriophages in a mouse model. Cell Host Microbe 25, 803\u2013814 e805 (2019).","journal-title":"Cell Host Microbe"},{"key":"72178_CR106","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/j.chom.2023.03.013","volume":"31","author":"J Shen","year":"2023","unstructured":"Shen, J. et al. Large-scale phage cultivation for commensal human gut bacteria. Cell Host Microbe 31, 665\u2013677 e667 (2023).","journal-title":"Cell Host Microbe"},{"key":"72178_CR107","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.1038\/s41416-022-02013-z","volume":"127","author":"M Seifert","year":"2022","unstructured":"Seifert, M. et al. Impact of the selective A2(A)R and A2(B)R dual antagonist AB928\/etrumadenant on CAR T cell function. Br. J. Cancer 127, 2175\u20132185 (2022).","journal-title":"Br. J. Cancer"},{"key":"72178_CR108","doi-asserted-by":"publisher","first-page":"4339","DOI":"10.1158\/1078-0432.CCR-24-0480","volume":"30","author":"LJ Zeverijn","year":"2024","unstructured":"Zeverijn, L. J. et al. The innate immune landscape of dMMR\/MSI cancers predicts the outcome of nivolumab treatment: results from the drug rediscovery protocol. Clin. Cancer Res. 30, 4339\u20134351 (2024).","journal-title":"Clin. Cancer Res."},{"key":"72178_CR109","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1016\/j.cell.2016.05.041","volume":"165","author":"A Koh","year":"2016","unstructured":"Koh, A., De Vadder, F., Kovatcheva-Datchary, P. & Backhed, F. From dietary fiber to host physiology: short-chain fatty acids as key bacterial metabolites. Cell 165, 1332\u20131345 (2016).","journal-title":"Cell"},{"key":"72178_CR110","doi-asserted-by":"publisher","DOI":"10.1002\/mnfr.202101019","volume":"66","author":"R Garcia-Villalba","year":"2022","unstructured":"Garcia-Villalba, R. et al. Urolithins: a comprehensive update on their metabolism, bioactivity, and associated gut microbiota. Mol. Nutr. Food Res. 66, e2101019 (2022).","journal-title":"Mol. Nutr. Food Res."},{"key":"72178_CR111","doi-asserted-by":"crossref","unstructured":"Tennoune, N., Andriamihaja, M. & Blachier, F. Production of indole and indole-related compounds by the intestinal microbiota and consequences for the host: the good, the bad, and the ugly. Microorganisms 10, 930 (2022).","DOI":"10.3390\/microorganisms10050930"},{"key":"72178_CR112","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/s41392-024-01811-6","volume":"9","author":"JS Fleishman","year":"2024","unstructured":"Fleishman, J. S. & Kumar, S. Bile acid metabolism and signaling in health and disease: molecular mechanisms and therapeutic targets. Signal Transduct. Target Ther. 9, 97 (2024).","journal-title":"Signal Transduct. Target Ther."},{"key":"72178_CR113","doi-asserted-by":"crossref","unstructured":"Martinez-del Campo, A. et al. Characterization and detection of a widely distributed gene cluster that predicts anaerobic choline utilization by human gut bacteria. mBio 6, e00042-15 (2015).","DOI":"10.1128\/mBio.00042-15"},{"key":"72178_CR114","doi-asserted-by":"publisher","DOI":"10.1080\/19490976.2024.2446374","volume":"17","author":"WK Wu","year":"2025","unstructured":"Wu, W. K. et al. Gut microbes with the gbu genes determine TMAO production from L-carnitine intake and serve as a biomarker for precision nutrition. Gut Microbes 17, 2446374 (2025).","journal-title":"Gut Microbes"},{"key":"72178_CR115","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/j.cell.2020.02.016","volume":"180","author":"I Nemet","year":"2020","unstructured":"Nemet, I. et al. A cardiovascular disease-linked gut microbial metabolite acts via adrenergic receptors. Cell 180, 862\u2013877 e822 (2020).","journal-title":"Cell"},{"key":"72178_CR116","doi-asserted-by":"crossref","unstructured":"Bottcher, J., Sibon, O. C. M. & El Aidy, S. Coenzyme A metabolism: a key driver of gut microbiota dynamics and metabolic profiles. FEMS Microbiol. Rev. 49, fuaf051 (2025).","DOI":"10.1093\/femsre\/fuaf051"},{"key":"72178_CR117","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1016\/j.cell.2020.05.001","volume":"181","author":"B Javdan","year":"2020","unstructured":"Javdan, B. et al. Personalized mapping of drug metabolism by the human gut microbiome. Cell 181, 1661\u20131679 e1622 (2020).","journal-title":"Cell"},{"key":"72178_CR118","doi-asserted-by":"publisher","DOI":"10.1126\/science.abo2296","volume":"380","author":"M Fidelle","year":"2023","unstructured":"Fidelle, M. et al. A microbiota-modulated checkpoint directs immunosuppressive intestinal T cells into cancers. Science 380, eabo2296 (2023).","journal-title":"Science"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-72178-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-72178-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-72178-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T12:04:22Z","timestamp":1781525062000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-72178-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,21]]},"references-count":118,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["72178"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-72178-1","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,21]]},"assertion":[{"value":"11 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"E. Voest is the founder and current member of the supervisory board of the Hartwig Medical Foundation, an independent non-executive director and shareholder of Sanofi, a co-founder and shareholder of Mosaic Therapeutics, and a board member and founder of the Centre for Personalised Cancer Treatment. He has received clinical study grants from Amgen, AstraZeneca, Bayer, BMS, Boehringer Ingelheim, Clovis, Eisai, Eli Lilly, GSK, Ipsen, Johnson & Johnson, MSD, Novartis, Pfizer, Roche, Servier, Incyte, MRM Health and Sanofi, all paid to the Netherlands Cancer Institute. C. Toner-Bartelds, I. Mimpen, M. Parra-Martinez and B. Burgering declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5274"}}